Effect of FN1 mutation on outcomes of fibronectin glomerulopathy in a systematic review and meta-analysis

Abstract

Background. Fibronectin glomerulopathy is an inherited kidney disease that is characterized with extensive depositions of fibronectin in mesangium and subendothelial space. The aim of study is to assess effect of fibronectin gene on decreased renal function and likeliness of recurrence of the disease after kidney transplantation. Materials and methods. In retrospective descriptive studies, fifty-seven patients with fibronectin glomerulopathy were enrolled in this research. Relative risk and Odds ratio for assessing effect measures of risk factor on outcomes of disease were used. Results. Of fifty-seven patients with fibronectin glomerulopathy, thirty-six patients (36/57, 63.1 %) were male and twenty-one patients were female (21/57, 36.8 %). Relative risk and Odds ratio of end-stage kidney disease (ESKD) in nephrotic-range proteinuria versus non-nephrotic range proteinuria were assessed 1.33 and 1.39, respectively. Relative risk and Odds ratio of end-stage kidney disease with kidney replacement therapy (KRT) in patients with positive FN1 gene (as risk or contributing factor) versus patients with negative FN1 gene was assessed 0.66 and 0.50, respectively. Risk of recurrence after kidney transplant with nephrotic-range proteinuria was assessed 0.83 (95% confidence interval of 0.1213 to 5.7244) and odds ratio of recurrence after kidney transplant with nephrotic proteinuria versus non-nephrotic range proteinuria was assessed 0.75 (95% confidence interval of 0.03757 to 14.9733) in the current research. Conclusions. Relative risk and odds ratio of end-stage kidney disease in nephrotic-range proteinuria versus non-nephrotic range proteinuria were assessed 1.33 and 1.39, respectively. Therefore, it appears risk of fibronectin gene 1 on end-stage kidney disease with kidney replacement therapy be low.